US › Healthcare

Indaptus Therapeutics Inc (INDP)

US · Healthcare · Biotechnology

$1.36+3.82%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.5M

Profit YoY

+43.9%

EPS

$-9.19

EPS estimate

$-4.36

EPS came in at -9.19 against a street estimate of -4.36 — a miss of 110.8%.

Key statistics

Market cap

$171.9M

Forward P/E

0.0

P/B

137.74

Book value

$0.01

EPS (TTM)

$-12.70

52-week high

$8.69

52-week low

$0.92

50-day MA

$2.61

200-day MA

$2.44

Beta

1.14

Analyst view

Analysts rate Indaptus Therapeutics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $10.00.

Shareholding

Insiders

97.01%

Institutions

0.10%

Largest institutional holders

Fund	Stake
Citadel Advisors Llc	0.03%
Geode Capital Management, LLC	0.02%
Morgan Stanley - Brokerage Accounts	0.00%
Tower Research Capital LLC	0.00%
SBI Securities Co Ltd	0.00%
CWM, LLC duplicate	0.00%
Pine Valley Investments Ltd Liability Co	0.00%
Bank of America Corp	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Indaptus Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.